Product Of Nature Doctrine & CRISPR- Cas9 - Ethical Issues
Author: LawSphereX
Category: General Law
Published:
Updated:
PRODUCT OF NATURE DOCTRINE & CRISPR- CAS9:
ETHICAL ISSUES
Rushmitha, B.A. LL.B., (Hons)., LLM, (Department of Intellectual Property Law) TNDALU, School of Excellence in Law, The Tamilnadu Dr. Ambedkar Law University (School of Excellence in Law)
ABSTRACT
The product of nature doctrine plays a crucial role in determining the patentability of genetic materials and biotechnological innovations, particularly in the context of advanced gene-editing technologies like CRISPR-Cas9. This doctrine asserts that natural phenomena, including naturally occurring genes and genetic sequences, cannot be patented, as they are products of nature. However, the emergence of CRISPR technology has blurred the lines between natural and synthetic, leading to complex legal and ethical challenges surrounding the patenting of isolated DNA sequences and genetically modified organisms. This abstract explores the implications of the product of nature doctrine as it pertains to CRISPR-Cas9, emphasizing the need for clarity in patent laws to accommodate innovations that arise from significant human intervention.
Furthermore, ethical issues, including concerns over unintended genetic consequences, social inequality, and the potential for eugenics, are examined. The ethical considerations surrounding the use of CRISPR for germline editing raise questions about individual autonomy, consent, and the long-term impacts on future generations. As CRISPR technology continues to advance, it is imperative to navigate the intersection of legal frameworks and ethical standards thoughtfully. Establishing comprehensive guidelines that address both patentability and ethical implications will be essential for fostering responsible innovation while safeguarding public health and social equity. This exploration underscores the urgency of engaging diverse stakeholders in dialogue and developing frameworks that balance scientific progress with ethical responsibility.
Keywords: Genetic Materials, Biotechnological Innovations, CRISPR- Cas9 Patents, Human Intervention in Biotechnology, Genetic Engineering Innovation.
CHAPTER-I
INTRODUCTION:
The main objective of the patent system has been to promote research and innovation to increase favorable results. Gene patenting has become a crucial aspect of intellectual property rights as science progresses. It is regarded as a major scientific advance, and many are attempting to obtain patents for their medically significant gene modifications. According to the restriction on patenting under this criterion, a patent will be considered invalid if it concerns a naturally occurring substance or a natural phenomenon, among other things. Biotechnology patents often raise patentability issues because of their close relationship to nature and use of natural elements to achieve particular goals. Particularly, patents based on genes and nucleic acids have generated controversy worldwide.
This technological development has ethical ramifications that go well beyond simple legal categorizations. The potential of CRISPR-Cas9 to alter the human genome presents significant issues regarding intergenerational justice, human dignity, and genetic enhancement. Determining the proper boundaries of genetic modification is a challenge for scientists and ethicists, especially when it comes to inherited alterations that may have an impact on future generations. Concerns regarding biosafety, regulation, and fair access to therapeutic applications have also arisen as a result of the democratization of genetic engineering brought about by the accessibility and relative ease of use of
CRISPRR
TECHNOLOGY.
The conventional Product of Nature theory is under growing pressure to change as society works through these issues. The doctrine must strike a balance between safeguarding basic genetic resources for research and development and defending ownership rights, which encourage innovation and investment in biotechnology.
LITERATURE REVIEW:
The Product of Nature Doctrine and Biotechnology In “The Product of Nature Doctrine in Biotechnology Patent Law,” Robert Cook- Deegan (2019) explores how the doctrine has evolved, particularly in the wake of biotechnological advancements. The paper examines landmark cases, such as Diamond v. Chakrabarty and Association for Molecular Pathology v. Myriad Genetics, analyzing how the doctrine shapes the patentability of genetic materials. Cook-Deegan highlights the tension between encouraging innovation and maintaining public access to natural resources, setting the stage for discussions on CRISPR and its implications for patent law. CRISPR-Cas9: A Revolution in Gene Editing In “CRISPR-Cas9 Gene Editing: A Technological Perspective,” Jennifer Doudna and Emmanuelle Charpentier (2014) detail the development and applications of CRISPR- Cas9 technology.
They describe its precision in targeting genetic sequences and the implications for medical and agricultural fields. The authors note that while CRISPR has significant potential for therapeutic applications, it also raises questions about intellectual property and the moral ramifications of editing the human genome. Ethics of Gene Editing and the Designer Baby Debate In “Ethics of Gene Editing: A Global Perspective,” Francis Fukuyama (2016) discusses the ethical implications of genetic modification, particularly in the context of designer babies. Fukuyama critiques the potential for CRISPR to exacerbate social inequalities and reintroduce eugenic ideologies. He emphasizes the need for regulatory frameworks that prevent the misuse of gene editing technologies and ensure equitable access, arguing that ethical discussions must accompany technological
In “The Ethical Implications of Patenting Genetic Materials,” Rebecca S. Eisenberg (2018) investigates the intersection of patent law and bioethics concerning the product of nature doctrine. Eisenberg argues that patenting naturally occurring genes undermines the ethical principle of sharing genetic knowledge for public benefit. The paper calls for a re-evaluation of patent laws to reflect ethical considerations, particularly in light of CRISPR technology's capabilities. Social Justice and Access to CRISPR Technology In “Gene Editing and Social Justice: The Unequal Access to CRISPR Technologies,” Ruha Benjamin (2019) analyses the implications of CRISPR technology on social inequalities. Benjamin argues that access to gene editing could lead to a divide between those who can afford enhancements and those who cannot, exacerbating existing disparities in health and opportunity.
The paper advocates for policies that promote equitable access to genetic technologies while addressing ethical concerns about eugenics and discrimination. Long-Term Consequences of Gene Editing In “Long-Term Health and Environmental Implications of CRISPR-Cas9,” Rachael B. W. Lee et al. (2020) assess the potential long-term effects of gene editing on human health and the environment. The authors highlight concerns about unintended consequences resulting from CRISPR interventions, including off-target effects and ecological disruptions. The paper emphasizes the importance of comprehensive risk assessments and ethical guidelines to safeguard future generations from unforeseen repercussions.
RESEARCH GAP:
Insufficient Exploration Of The Ethical Implications Of Gene Patenting, Including Issues Of Genetic Privacy And The Commercialization Of Genetic Information.
RESEARCH PROBLEM:
Ø How does the gene patenting affect the pace and direction of innovation in the biotechnology sector? Ø What are the ethical and legal challenges associated with gene patenting and how do these challenges influence regulatory practices?
RESEARCH OBJECTIVE:
1. To Identify and analyze the potential impact of gene editing.
2. To examine the effectiveness of the current regulatory framework in addressing
ethical and moral concerns of gene editing.
HYPOTHESES:
Gene patenting positively influences innovation in biotechnology by providing financial incentives and legal protection for new genetic discoveries and technologies. Gene patenting restricts access to genetic tests and therapies in developing countries by increasing the cost and limiting availability of patented genetic technologies.the ethical concerns surrounding gene patenting, such as the ownership of genetic material and potential for misuse, significantly affect public perception and regulatory approaches to gene patents.
RESEARCH METHODOLOGY:
Researcher would employ doctrinal research approach for this study. Primary and secondary sources are used to compile the study data. Primary sources include parliamentary legislation, existing papers, and publications on the topic. Secondary sources are the legal materials, documentary sources, books, these, articles, reports, research papers, libraries, internet and previously decided judicial case laws all feature prominently in this investigation.
CHAPTER -II
GENE EDITING:
Genome editing, also known as gene editing, is a field of research focused on altering the genes of living organisms to enhance our understanding of gene function and develop treatments for genetic or acquired diseases. This process allows for the correction, insertion, or deletion of nearly any DNA sequence across various types of cells and organisms. Although DNA modification techniques have been around for decades, recent advancements have made genome editing more efficient, costeffective, and faster. The technique is based on the earlier discovery that when a section of DNA is broken, the cell’s repair mechanism automatically attempts to mend it. Genome editing leverages this natural repair process. Modern genome editing methods include protein-engineered tools such as zinc-finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and Mega nucleases.
Another key method is CRISPR/Cas9, which stands for clustered regularly interspaced short palindromic repeats. Genome editing holds significant potential for preventing and treating human diseases. Currently, it is being used in research labs with cells and animal models to better understand diseases. Scientists are still evaluating whether genome editing is safe and effective for use in humans. This technology is being investigated in clinical trials for various conditions, including single-gene disorders like cystic fibrosis, hemophilia, and sickle cell disease. Additionally, genome editing shows promise in addressing more complex conditions, such as cancer, heart disease, mental illness, and HIV infection.
However, the use of genome editing technologies like CRISPR-Cas9 raises ethical concerns, particularly when it involves altering human genomesThis raises ethical issues, especially when considering the potential use of this technology to enhance normal human traits, such as height or intelligence.
GENE PATENTING:
The field of biotechnology has experienced significant and rapid growth, playing a crucial role in the overall advancement of the country. Since the discovery of DNA's structure in 1953, scientists have worked to identify the sequences and functions of these molecules, as well as find methods to manipulate them for industrial purposes. Gene patenting refers to the process of patenting methods for manipulating DNA and related chemical substances, including gene sequences and fragments that do not occur in their natural state. There are three main types of inventions associated with gene patents:
Ø
Diagnostics, which involves patenting methods for testing genetic variations;
Ø
Compositions of Matter, which protects inventions that arise from combining different genetic materials, such as drugs and vaccines; and
Ø
Functional Use, which pertains to discovering the roles of various genes in causing diseases.
PRODUCT OF NATURE DOCTRINE:
The "product of nature" doctrine in U.S. patent law evolved to prevent the patenting of newly discovered plants and animals1. However, with scientific progress, this doctrine became an obstacle to patenting microorganisms and biotechnological inventions. Under this rule, synthetic products that challenging to secure patents for genes. This doctrine also appears in Indian law. According to Section 3(c) of the Indian Patent Act2, both living and non-living substances cannot be patented. However, the Indian provision is more flexible compared to the U.S. law. In India, if a natural substance is transformed into a usable form, it may be eligible for patenting, giving the "product of nature" doctrine a distinct interpretation.
CHAPTER-III
CRISPR-Cas9: The latest developments in genetic technology highlight one of the most crucial intersections between scientific progress and its impact on existing legal frameworks. Gene editing, or genome editing, is a form of genetic engineering that alters an organism's DNA by adding, removing, or modifying genetic material within the genome. and the long-term effects on human evolution. As CRISPR continues to evolve, it necessitates thoughtful legal and ethical considerations to ensure its responsible application. CRISPR-Cas9 is based on a natural genome editing system used by bacteria as a defense against viruses. When bacteria are infected by viruses, they capture fragments of the viruses' DNA and incorporate them into their own DNA in a specific pattern, forming segments called CRISPR arrays. These arrays help the bacteria "remember" the viruses.
If the same or similar viruses attack again, the bacteria produce RNA segments from the CRISPR arrays that bind to matching parts of the viruses' DNA. The bacteria then use enzymes like Cas9 to cut the viral DNA, disabling the virus. Researchers have adapted this bacterial immune system for DNA editing. They design a small RNA molecule with a guide sequence that binds to a specific target in a cell's DNA, just as bacteria use Genome editing holds great promise for the prevention and treatment of human diseases. Currently, it is being used in research labs on cells and animal models to deepen our understanding of diseases. Scientists are still working to assess whether genome editing is safe and effective for human use.
This technology is being explored in clinical trials for a wide range of conditions, including single-gene disorders like cystic fibrosis, hemophilia, and sickle cell disease, as well as more complex diseases such as cancer, heart disease, mental illness, and HIV3.
APPLICATIONS OF CRISPR-CAS9:
CRISPR-Cas9 has revolutionized biology and medicine due to its precise gene-editing capabilities, enabling breakthroughs in several key areas:
MEDICAL RESEARCH AND GENE THERAPY:
TREATING GENETIC DISEASES:
CRISPR can correct mutations that cause genetic disorders. For instance, it offers hope for treating diseases like sickle cell anemia, cystic fibrosis, and muscular dystrophy, which are all caused by single-gene mutations. - By precisely editing or replacing defective genes, CRISPR has the potential to cure or alleviate these conditions, providing a targeted approach to gene therapy. Cancer Research: - CRISPR is being used to explore innovative cancer treatments. Researchers can edit the DNA of cancer cells to inhibit their growth, target them more effectively, or make them more vulnerable to existing therapies. - Additionally, CRISPR can be used to enhance the body’s immune system by modifying immune cells to better recognize and attack cancer cells, opening new avenues in immunotherapy.
- CRISPR’s flexibility and accuracy in these applications represent a paradigm shift in medical research, offering hope for previously untreatable genetic conditions and transforming how we approach cancer therapy.
CROP IMPROVEMENT:
CRISPR is employed to engineer crops with enhanced resistance to pests, diseases, and environmental stressors such as drought or soil salinity. By enabling plants to withstand adverse conditions, CRISPR can significantly improve agricultural productivity and reduce dependency on chemical pesticides, contributing to sustainable farming and greater food security. Nutritional Enhancement: - Scientists use CRISPR to boost the nutritional content of crops by altering genes responsible for essential nutrients. For example, researchers are working on developing crops with higher levels of vitamins, minerals, or healthier fats, potentially addressing global nutritional deficiencies.
B. BASIC RESEARCH
CRISPR-Cas9 facilitates the study of gene function by allowing researchers to "knock out" or disable specific genes, helping to observe the resulting biological effects. This technique enhances the understanding of genetic diseases, cellular processes, and mechanisms of development, providing crucial insights for the discovery of new treatments and therapies. CRISPR’s applications in agriculture and basic research are helping to reshape both food production and scientific exploration, further expanding its potential to solve global challenges in health and sustainability.
CRISPR CAS9 ETHICAL CONCERNS:
However, genome editing, particularly using tools like CRISPR-Cas9, raises significant ethical concerns, especially when it involves altering human genomes. Most genome editing today focuses on somatic cells—cells other than germline cells (sperm and egg cells). Changes in somatic cells affect only specific tissues and are not passed on to future generations. In contrast, editing the genes in germline cells or embryos could result in heritable changes, raising ethical issues about the potential to enhance normal human traits such as height or intelligence. cells and embryos is currently illegal in the United States and many other countries. This reflects a cautious approach to the powerful potential of genome editing technology and its far-reaching consequences.
GERM-LINE EDITING:
A designer baby is created through a form of germ-line editing, which
involves altering genes in sperm, eggs, or early-stage embryos. These genetic modifications are inheritable, meaning the altered genes can be passed on to future generations in addition to the offspring produced. The primary goal of germ-line editing is to replace one gene variant with another, producing a different effect by modifying the DNA sequence in an embryo. In theory, designer babies could be free from genetic disorders such as thalassemia, cystic fibrosis, and many others. The current conversation around CRISPR-Cas9 technology has expanded to include the idea of designer babies, where parents could potentially select specific traits for their children, aiming to create an optimal genetic version of them4.
DESIGNER BABY:
The term “designer babies” refers to the concept of genetically altering embryos to select or enhance specific traits, such as intelligence, physical appearance, or resistance to certain diseases. While this idea has long been a fixture of science fiction, the development of gene-editing technologies like CRISPR has brought it closer to reality. These advancements raise significant ethical concerns, as altering the human genome in this way could have unpredictable consequences and potentially lead to societal issues, such as inequality and the commodification of human traits. The possibility of creating "designer babies" has intensified debates surrounding the ethical, moral, and regulatory implications of genetic engineering5.
ETHICAL CONCERNS:
1. Unintended Consequences: The ethical concerns surrounding designer babies are
further intensified by the potential for unintended consequences linked to gene-editing techniques, such as CRISPR/Cas9. Although the Cas9-gRNA complex is designed to accurately target and modify specific genes, it can sometimes unintentionally target
other regions of the genome. This off-target cutting can cause mutations and undesired alterations in genes that were not originally intended for modification. While CRISPR technology holds promise for treating genetic disorders, there remains a considerable knowledge gap regarding the lasting effects of such treatments. The interactions between edited genes and other genes in the human body, and the consequences of these interactions over time, are still not fully understood. For instance, the deletion of the CCR5 gene, which shows potential for preventing HIV infection, raises concerns about its broader role in the immune system. A 2019 study published in Nature found that deleting CCR5 in mice increased their susceptibility to West Nile virus and decreased their survival rates. This highlights the complexities of gene functions that extend beyond their immediate therapeutic targets.
These unknowns demand a careful and thoughtful approach to gene editing6. Given these risks, it is critical to rigorously evaluate the safety of gene-editing techniques before applying them in humans. A cautious approach is essential to ensure that both current and future generations are protected from unintended consequences. Any decision to alter the human genome, particularly in the germline, carries profound implications for the future of humanity, shaping not only individual lives but also the genetic makeup of future populations. SOCIAL INEQUALITY: One of the most significant concerns about the rise of CRISPR technology is its potential to exacerbate existing social and economic disparities.
If access to gene-editing technologies remains restricted to wealthier individuals, they may have the opportunity to enhance their children genetically, creating a class of genetically privileged individuals. This could lead to a new form of inequality where those who can afford genetic enhancements outperform others in health, intelligence, and physical abilities, perpetuating social divisions and creating a genetic underclass7. This scenario raises profound ethical questions about fairness and the societal impact of such genetic inequalities
EUGENICS: CRISPR's ability to alter genes has reignited concerns about the reemergence of eugenics, a discredited and widely condemned movement that aimed to improve the genetic "quality" of populations by promoting desirable traits and eliminating perceived undesirable ones. In the early 20th century, eugenics was used to justify harmful practices, including forced sterilization and racial cleansing, most notoriously by the Nazi regime. This could create a genetically homogeneous society that discriminates against those with disabilities, genetic conditions, or simply traits deemed undesirable, fostering a resurgence of genetic elitism and reducing genetic diversity, which is essential for the resilience and adaptability of populations8. CONSENT AND AUTONOMY: The ethical principle of autonomy is challenged when considering gene editing in unborn children.
Since these children cannot consent to having their genes altered, decisions are made by others—typically parents or medical professionals. This raises questions about who has the right to make such life-altering decisions: parents, society, or the individuals themselves? Moreover, the potential to influence traits that extend beyond treating diseases, such as physical appearance or intelligence, complicates matters, as it could involve imposing subjective parental or societal values on the child, potentially infringing on the child’s future autonomy. MORAL AND RELIGIOUS OBJECTIONS: Many people hold moral or religious objections to genetic modifications, particularly when it comes to altering human embryos. For some, the practice of modifying human genetics is seen as unnatural or an overreach of human intervention, often referred to as "playing God.
" This viewpoint raises above the human nature.
CHAPTER- IV
GENE PATENTING IN USA AND INDIA:
UNITED NATION OF AMERICA:
The "product of nature" doctrine has been a significant part of U. S. patent law since the 19th century and continues to influence legal decisions today. In May 2019, a U. S. district court denied a patent for a purified form of cannabinoids claimed in UCANN’s U. S. Patent No. 9,730,911. This patent application sought protection for a liquid cannabinoid formulation containing at least 95% of specific cannabinoids (such as CBD or THC). The court upheld the "product of nature" doctrine, refusing to grant the patent. In the notable case of Diamond v. Chakrabarty9, a patent was sought for both the process and the final product involving a genetically modified microorganism that could break down crude oil. This case marked the first instance in U. S. patent history where the patentability of a natural object was not questioned.
Surprisingly, Chakrabarty was granted a patent for the process as a trade secret, but not for the genetically modified bacteria itself. The court ruled that the bacteria was a natural product, which falls outside the scope of patentable subject matter, as living organisms and microorganisms are not considered patentable under the doctrine. The decision in Diamond v. Chakrabarty highlighted the strict application of the "product of nature" doctrine, which serves as a barrier to patenting genetically modified organisms (GMOs) that are created using recombinant DNA technology. However, despite this ruling, the processes used to produce GMOs remain patentable in the U. S. This flexibility arises from the more liberal interpretation of the doctrine, as seen in the case of Merck & Co. v. Olin Mathieson Chemical Corp.
, where the court ruled that the product was patent-eligible because it existed in a different form in nature than the one produced by the patentee.
The key distinction between patentable and non-patentable products lies in whether the product exists in the same form in nature as the one produced by the patentee. U.S. patent laws apply the "product of nature" doctrine more broadly, focusing on whether an identical product already occurs in nature. If the product is found in a different form or altered significantly by human intervention, it may be considered patent-eligible.
INDIA:
The Indian Patents Act, under Section 3(c), states that the mere discovery of a scientific principle, the formulation of an abstract theory, or the discovery of any living or non-living substance found in nature is not patentable. Furthermore, Section 3(i) specifies that plants and animals, in whole or in part, including seeds, varieties, and species, as well as biological processes used for the production or propagation of plants and animals, cannot be patented, with the exception of microorganisms. While genes that naturally occur are not patentable under Section 3(c), it is important to acknowledge the significant skill required to identify, locate, and isolate a gene. Despite this complexity, the natural occurrence of the gene still renders it unpatentable under the current law10.
The exclusion of parts of animals and plants from patentability under Indian law must be carefully considered, as it is phrased differently from the TRIPS Agreement, which excludes plants and animals without explicitly mentioning their parts. This distinction calls for a review of the Patent Practice Manual issued by the Indian Patent Office. In the 2008 draft manual, this annex was no longer present. The Dimminaco decision supported Section 3(j) of the Patents Act, which clarified the conditions under which microorganisms are patentable, but did not address patentability of other biotechnological inventions.
In the 2005 draft manual, a dedicated annex on biotechnological and pharmaceutical inventions clearly stated that living entities of artificial origin, such as transgenic animals and plants, and any part thereof, were not patentable. Additionally, it affirmed that living entities of natural origin, including animals, plants, plant varieties, seeds, species, and genes, were not considered patentable. However, recombinant DNA and plasmids were patentable if there was substantial human intervention involved.
Under the "unity of an invention" section, the manual provides an example indicating that when a genetically modified gene or amino acid sequence is novel, involves an inventive step, and has industrial applicability, the following claims can be made: - The gene or amino acid sequence itself, - A method of expressing this sequence, - An antibody against this protein/sequence, - A kit made from the antibody or sequence. The final version of the Manual of Patent Practice and Procedure, released in 2011, did not expand on these matters, retaining only the provisions requiring a sequence listing from the patentee and the bullet points under "unity of an invention. " Notably, the
2011 manual did not explicitly address the need for substantial human intervention,
which had been mentioned in earlier drafts. This lack of elaboration on substantial human intervention leaves some ambiguity regarding the patentability of biotechnological inventions11. The patent for "An Isolated Nucleic Acid Molecule Comprising an Allele of a Genetic Polymorphism Linked to Resistance to Enterotoxigenic Escherichia coli (ETEC)" involves a nucleic acid sequence related to resistance against a specific strain of E. coli in pigs. The invention encompasses methods for identifying this sequence using specially designed probes and primers.
The first claim covers the sequence responsible for the trait of resistance in pigs, which naturally occurs in the animal, as well as the man-made probes and primers used for identifying the gene. Interestingly, the first examination report does not raise objections concerning the animal origin of the gene or the fact that the first claim pertains to an isolated gene sequence. This suggests that animal genes, including those naturally occurring, can be patentable in India, provided they are isolated and associated with a specific trait or invention, such as in this case. The patent also covers the artificial components used to detect the gene, reinforcing the scope for patenting genetic sequences in the context of genetic resistance and biotechnology in India. In the recent case of Monsanto Technology LLC v. Nuziveedu Seeds Ltd12.
, the Division Bench of the Delhi High Court ruled that genetically modified plants, seeds, and gene sequences imparting genetic traits to plants are not patentable under Indian law. This decision aligns with India's patent laws, which exclude plants and animals, as well as biological processes for their production, from patent eligibility. However, this ruling was set aside by the Supreme Court of India due to the complexity of the case and the need for a thorough re-examination of the evidence. The Supreme Court did not provide a final decision on the patentability of isolated DNA or complementary DNA (cDNA). As a result, India's stance on the patenting of these genetic materials remains unclear, with no definitive legal position yet established.
This ongoing uncertainty highlights the need for further legal and policy clarification regarding the patentability of biotechnological inventions, including isolated genetic material, in India.
CHAPTER -V
ETHICAL ISSUES:
Moral Implications of Gene Patenting, CRISPR-Cas9, and Designer Babies The intersection of gene patenting, CRISPR-Cas9 technology, and the concept of designer babies raises significant moral and ethical questions. These issues are increasingly pressing as advances in biotechnology make once-abstract concepts a tangible reality. Below are several key moral implications associated with these developments.
HUMANS AS COMMODITIES:
The notion that humans can be treated as commodities—specifically, in terms of their genetic structure—raises serious ethical concerns. Patenting genes and genetic modifications could lead to the perception of human beings as products subject to ownership and trade. If companies can patent human genes, there is a risk that individuals might be seen as mere vehicles for genetic traits, with their worth assessed based on the desirability of their genetic makeup. This commodification of human life challenges the inherent dignity and value of individuals, undermining the principle that all humans possess equal rights and should not be owned or exploited.
ETHICAL BOUNDARIES AND GENETIC MANIPULATION:
The manipulation of genetic material, particularly in the context of creating designer babies or genetically modified organisms, raises profound ethical questions about the limits of scientific intervention. The case of Dolly the sheep— the first mammal cloned from an adult somatic cell—highlights the ethical dilemmas posed by crossing genetic boundaries. This instance led to concerns about "playing God" and the potential consequences of manipulating life at fundamental levels. Ethical lines may become blurred when deciding what constitutes acceptable genetic modification. For instance, is it ethical to create embryos that possess enhanced traits such as intelligence or beauty? Such actions could lead to societal pressures to conform to specific genetic ideals, ultimately compromising individuality and diversity18.
Driving Forces: Innovation vs. Personal Gain The motivations behind gene patenting and the development of CRISPR technology merit scrutiny. While innovation in biotechnology can lead to significant advancements in healthcare and agriculture, the underlying incentives may also prioritize personal or corporate gain. The possibility of over-patenting genes can create a monopolistic environment, where profit-driven motives overshadow public health interests. This dynamic can lead to a scenario where access to life-saving treatments is restricted due to patent rights, further entrenching inequalities in global healthcare systems. Additionally, if personal gain drives the innovation, there may be less emphasis on ethical considerations, resulting in potential exploitation of vulnerable populations or individuals.
Over-Patenting and Global Injustice The trend toward aggressive gene patenting raises concerns about global injustice, particularly for low-income countries that may lack the resources to compete in biotechnology and healthcare. The over-patenting of genes could limit access to essential treatments and technologies for marginalized populations, exacerbating existing disparities in health outcomes. Furthermore, companies may prioritize profits over public good, leading to a situation where essential medicines are inaccessible to those who need them the most. This injustice not only raises moral concerns but also threatens the ethical principles of equity and justice that should underpin global healthcare. Informed Consent and Autonomy The ethical principle of informed consent is particularly pertinent in the context of gene editing and designer babies.
Parents may make decisions about their children's genetic traits without fully understanding the long-term implications. The autonomy of the child—who has no say in the genetic modifications being made— raises serious ethical questions. The potential to create a child with pre-determined traits compromises the individual's right to self-determination and personal identity. Furthermore, the societal pressures that may accompany designer babies could limit the freedom of future generations to define themselves on their own terms.
LEGAL ISSUES:
The legal implications surrounding the patentability of synthetically isolated DNA sequences, transformed versus natural criteria, and the specificity of gene use are complex and multifaceted. Here's an overview of these legal considerations:
1. Synthetically Isolated DNA Sequences and the Transformed vs. Natural
Criterion Synthetically Isolated DNA Sequences:
A synthetically isolated DNA sequence refers to a segment of DNA that has
been separated from its natural context and may have been altered or manipulated through laboratory techniques. To be patentable, the isolated sequence typically needs to meet several criteria: - Novelty: The sequence must not have been previously disclosed or known. - Non-obviousness: The modification or isolation must not be obvious to a person skilled in the field based on prior art. - Utility: The isolated sequence must have a specific and substantial utility, such as a therapeutic application or research use.
TRANSFORMED VS. NATURAL CRITERION:
The legal distinction between transformed (synthetic or modified) and natural DNA sequences is critical for determining patent eligibility. In jurisdictions like the United States, the U.S. Patent and Trademark Office (USPTO) has allowed patents on modified or synthetic sequences if they exhibit a significant difference in function or structure from their naturally occurring counterparts. Conversely, natural sequences that exist without human intervention may be excluded from patentability, as established in cases like Association for Molecular Pathology v. Myriad Genetics, where the Supreme Court ruled that naturally occurring DNA segments are not patentable.
CONCLUSION:
Addressing the implications of the product of nature doctrine and the ethical issues surrounding CRISPR-Cas9 technology requires a multifaceted approach. By clarifying legal frameworks, promoting open access, establishing robust ethical guidelines, and fostering public engagement, society can navigate the complexities of gene editing responsibly and equitably. This will ensure that the benefits of these technologies are maximized while minimizing risks and ethical dilemmas. The convergence of CRISPR-Cas9 technology with the Product of Nature doctrine marks a turning point in scientific, legal, and ethical debate and necessitates a sophisticated and flexible approach to genetic innovation.
It is becoming more and more obvious that conventional legal frameworks are unable to adequately address the revolutionary potential of gene editing technologies as we traverse the intricate landscape of biotechnological innovation. The main difficulty is not drawing strict lines but rather coming up with flexible regulatory frameworks that may strike a balance between scientific advancement, morality, human rights, and the welfare of society. The inherent flaws in the Product of Nature theory have been made clear by CRISPR-Cas9, which has also shown how ambiguous and complicated the line separating natural and manmade genetic material is. This innovation in technology forces us to basic ideas about genetic ownership, ideas, and the essence of biological creativity.
The ethical ramifications touch on deep issues of human agency, genetic engineering, and intergenerational responsibility, going well beyond legal classifications. It is imperative that policymakers, scientists, ethicists, and legal professionals work together to create comprehensive frameworks that can handle the complex issues raised by gene editing technology. This calls for an all-encompassing strategy that takes into account the wider social, intellectual, and moral ramifications of genetic alteration in addition to its scientific and legal aspects.
RECOMMENDATION AND SUGGESTIONS:
Ø Promote Transparent Research and Development Encourage transparency in how CRISPR-Cas9 is developed and applied. This includes open access to research methodologies and findings, especially in relation to natural genetic sequences and their modification. Ø Define Clear Patent Guidelines Reassess the Product of Nature Doctrine to establish clearer boundaries on what constitutes a "natural" product versus a patentable invention when using CRISPR. This ensures innovation without overreach into what should remain public domain. Ø Uphold Human Dignity Enforce strict prohibitions on using CRISPR for germline editing that may lead to designer babies or other practices that commodify human traits, ensuring ethical standards that prioritize human dignity.
Ø Enhance Public Awareness and Engagement Launch education campaigns to inform the public about CRISPR-Cas9 and the ethical implications of editing genetic material, fostering an informed discourse and consensus on acceptable uses. Ø Strengthen International Governance Create an international regulatory framework to guide the application of CRISPR and address ethical concerns, ensuring consistent standards across countries while respecting cultural diversity. Ø Prioritize Environmental Ethics Conduct rigorous environmental impact assessments before using CRISPR to modify ecosystems, such as introducing gene drives to control invasive species, to prevent unintended ecological disruptions.
Ø Encourage Equity in Access Implement measures to prevent the monopolization of CRISPR technology, ensuring equitable access to its benefits, particularly for low-income countries and marginalized communities. Ø Develop Ethical Guidelines for Non-Human Applications Establish frameworks to guide CRISPR applications in agriculture and animal research, balancing innovation with considerations for animal welfare and biodiversity conservation.
BIBLIOGRAPHY:
v John M Conley, Gene Patents and the Product of Nature Doctrine, Vol 84, Issue 1, Chicago -Kent Law review v Product of Nature Doctrine: Myrids effect beyond Nucleic acids, Columbia University v John M Conley and Roberte Makowshi, Back to the Future: Rethinking the Product of Nature Doctrine as a Barrier to Biotechnology Patents, v Christoper Beauchamp, Patenting Nature: A Problem of History, Brooklym Law School, Brooklynworks. v Archana Gadekar, A.R.T.: Are We Heading towards Designer Babies, 3 INDIAN J.L. & JUST. 56 (2012).
v Devina Rathod, Human Gene Patenting in India: An Analysis, 2 JUS CORPUS L.J. 851 (2022).
v James Brown, Genetic Modification: Should We Cross the Rubicon and Legalise Human Germline Genome Editing? Avoiding 'Designer DNA' Using a Regulatory Approach Based on Human Rights Principles, 4 EDINBURGH STUDENT L. REV. 82 (2021).
v Lawrence E. Gill, Designer Eugenics: Germline's Future Interests, 5 AVE MARIA INT'l L.J. 112 (2016) v Bratislav Stankovic, "It's a Designer Baby!" - Opinions on Regulation of Preimplantation Genetic Diagnosis, 9 UCLA J.L. & TECH. 1 (2005). v Rumiana Yotova, Regulating Genome Editing under International Human Rights Law, 69 INT'l & COMP. L.Q. 653 (2020). v Janice M. Mueller, Biotechnology Patenting in India: Will Bio-Generics Lead a Sunrise Industry to Bio-Innovation, 76 UMKC L. REV. 437 (2007).